The influence of valproic acid treatment on hair and serum zinc levels and serum biotinidase activity

European Journal of Paediatric Neurology

Volumn 13, Issue 5, 2009, Pages 439-443

  Yilmaz, Yunus ^a   Tasdemir, Haydar Ali ^a   Paksu, Muhammet Sukru ^a  

^a ONDOKUZ MAYIS UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Biotinidase activity; Valproic acid; Zinc

Indexed keywords

BIOTINIDASE; VALPROIC ACID; ZINC;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; ENZYME ACTIVITY; FEMALE; HAIR ANALYSIS; HAIR LOSS; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; TREATMENT DURATION; ZINC BLOOD LEVEL;

ALOPECIA; ANTICONVULSANTS; BIOTINIDASE; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HAIR; HUMANS; MALE; TIME FACTORS; VALPROIC ACID; ZINC;

EID: 68349113676     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2008.08.007     Document Type: Article

References (27)

1. Korkmazer N., Vurucu S., Demirkaya E., et al. Serum and liver tissue biotinidase enzyme activity in rats which were administrated to valproic acid. Brain Dev 28 (2006) 515-520
2. Schulpis K.H., Karikas G.A., Tjamouranis J., Regoutas S., and Tsakiris S. Low serum biotinidase activity in children with valproic acid monotherapy. Epilepsia 42 (2001) 1359-1362
3. Armutcu F., Ozerol E., Gurel A., et al. Effect of long-term therapy with sodium valproate on nail and serum trace element status in epileptic children. Biol Trace Elem Res 102 (2004) 1-10
4. Suzuki T., Koizumi J., Moroji T., et al. Effects of long-term anticonvulsant therapy on copper, zinc, and magnesium in hair and serum of epileptics. Biol Psychiatry 31 (1992) 571-581
5. Lerman-Sagie T., Statter M., Szabo G., and Lerman P. Effect of valproic acid therapy on zinc metabolism in children with primary epilepsy. Clin Neuropharmacol 10 (1987) 80-86
6. Hurd R.W., Van Rinsvelt H.A., Wilder B.J., Karas B., Maenhaut W., and De Reu L. Selenium, zinc, and copper changes with valproic acid: possible relation to drug side effects. Neurology 34 (1984) 1393-1395
7. Dreifuss F.E., and Langer D.H. Side effects of valproate. Am J Med 84 (1988) 34-41
8. Davis R., Peters D.H., and McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47 (1994) 332-372
9. Schmidt D. Adverse effects of valproate. Epilepsia 25 (1984) 44-49
10. Lewis-Jones M.S., Evans S., and Culshaw M.A. Cutaneous manifestations of zinc deficiency during treatment with anticonvulsants. Br Med J 290 (1985) 603-604
11. Shapiro J., Wiseman M., and Lui H. Practical management of hair loss. Can Fam Physician 46 (2000) 1469-1477
12. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
13. Daffron J.C., and Kasarskis E.J. Effect of valproic acid on zinc metabolism in the rat. Toxicol Lett 23 (1984) 321-325
14. Kuzuya T., Hasegawa T., Shimizu K., and Nabeshima T. Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients. Int J Clin Pharmacol Ther Toxicol 31 (1993) 61-65
15. Graf W.D., Oleinik O.E., Glauser T.A., Maertens P., Eder D.N., and Pippenger C.E. Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy. Neuropediatrics 29 (1998) 195-201
16. Altunbaşak S., Biatmakoui F., Baytok V., Hergüner O., Burgut H.R., and Kayrin L. Serum and hair zinc levels in epileptic children taking valproic acid. Biol Trace Elem Res 58 (1997) 117-125
17. Kürekçi A.E., Alpay F., Tanindi S., et al. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy. Epilepsia 36 (1995) 600-604
18. Kaji M., Ito M., Okuno T., et al. Serum copper and zinc levels in epileptic children with valproate treatment. Epilepsia 33 (1992) 555-557
19. Verrotti A., Basciani F., Trotta D., Pomilio M.P., Morgese G., and Chiarelli F. Serum copper, zinc, selenium, glutathione peroxidase and superoxide dismutase levels in epileptic children before and after 1 year of sodium valproate and carbamazepine therapy. Epilepsy Res 48 (2002) 71-75
20. Yuen W.C., Whiteoak R., and Thompson R.P. Zinc concentrations in leucocytes of patients receiving antiepileptic drugs. J Clin Pathol 41 (1988) 553-555
21. Tietz N.W. Textbook of clinical chemistry (1986), W.B. Saunders Company, Philadelphia p. 287-485, 619-763, 995-96, 1495-588
22. Sözüer D.T., Barutçu U.B., Karakoç Y., Yalçin E., and Onen S. The effects of antiepileptic drugs on serum zinc and copper levels in children. J Basic Clin Physiol Pharmacol 6 (1995) 265-269
23. Milne D.B. Trace elements. In: Burtis C.A., and Aschwood E.R. (Eds). Tietz textbook of clinical chemistry. 3rd ed. (1999), W.B. Saunders Company, Philadelphia 1029-1055
24. Coakley M.E., and Brown N.A. Valproic acid teratogenicity in whole embryo culture is not prevented by zinc supplementation. Biochem Pharmacol 35 (1986) 1052-1055
25. Keen C.L., Peters J.M., and Hurley L.S. The effect of valproic acid on 65Zn distribution in the pregnant rat. J Nutr 119 (1989) 607-611
26. Grier R.E., Heard G.S., Watkins P., and Wolf B. Low biotinidase activities in the sera of patients with impaired liver function: evidence that the liver is the source of serum biotinidase. Clin Chim Acta 186 (1990) 397-400
27. Bowden C.L. Valproate. Bipolar Disord 5 (2003) 189-202